Author:
Ying Yue,Hu Yue-Kai,Jin Jia-Lin,Zhang Ji-Ming,Zhang Wen-Hong,Huang Yu-Xian
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference16 articles.
1. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49:S185–95.
2. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV, GLOBE Study Group. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136(2):486–95.
3. Caroleo B, Galasso O, Staltari O, Girofrè C, De Sarro G, Guadagnino V, Gallelli L. Muscular damage during telbivudine treatment in a chronic hepatitis B patient. Muscles, Ligaments and Tendons Journal. 2011;1(2):57–60.
4. Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J Viral Hepat. 2012;19:732–43.
5. Zou XJ, Jiang XQ, Tian DY. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J Viral Hepat. 2011;18(12):892–6.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献